NCT04584307View on ClinicalTrials.gov

Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Elotuzumab

Elotuzumab 10-20mg/kg

DRUG

Pomalidomide

Pomalidomide 2mg

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Natalie Callendar

OTHER

NCT04584307 - Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant | Biotech Hunter | Biotech Hunter